Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 10/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7495078 | 0.93 | PDK4 (0.39) | PDK4GRM5GRM1NAMPTGPR119 | |
| SCHEMBL7494927 | 0.89 | USP2 (0.38) | PDK4GPR119ESR2NR1H2CNR2 | |
| SCHEMBL7476247 | 0.87 | PDE4D (0.35) | PDK4GRM5GRM1NAMPTGPR119 | |
| SCHEMBL29967028 | 0.84 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL19434355 | 0.81 | MEN1 (0.31) | — | |
| SCHEMBL590772 | 0.81 | QDPR (0.39) | NAMPT | |
| SCHEMBL7468708 | 0.81 | PDE4D (0.33) | GPR119ESR2NR1H2CNR2PDE4A | |
| SCHEMBL6856969 | 0.80 | CNR2 (0.32) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1733879 | 0.80 | PDK4 (0.51) | PDK4GRM5GRM1NAMPTGPR119 | |
| SCHEMBL597913 | 0.78 | PDK4 (0.45) | PDK4GRM5GRM1NAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4291562-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116783202-A | Thienopyrrole compounds | 吉利德科学公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3440078-B1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD (IN) | 2022-09-28 | — | — | EP | disclosed |
| WO-2022173722-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| EP-0982304-B1 | Piperidine derivatives having effects on serotonin related systems | LILLY CO ELI (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6436964-B1 | HETEROCYCLIC AMINES, USED AS SERETONIN REUPTAKE INHIBITORS AND RECEPTOR ANTAGONISTS, ANTIDEPRESSANTS | ELI LILLY AND COMPANY | 2002-08-20 | — | — | US | disclosed |
| EP-1146045-A1 | Piperidine derivatives having effects on serotonin related systems | ELI LILLY AND COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001023381-A1 | PIPERIDINE DERIVATIVES AS REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0982304-A1 | Piperidine derivatives having effects on serotonin related systems | ELI LILLY AND COMPANY (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-2000000198-A1 | PIPERIDINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5998438-A | SEROTONIN RECEPTOR ANTAGONIST; HEADACHE THERAPY | ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 1999-12-07 | — | — | US | disclosed |
| EP-0944595-A1 | 5-CYCLO INDOLE COMPOUNDS AS 5-HT1D RECEPTOR LIGANDS | Allelix Biopharmaceuticals Inc. (CA) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023587-A1 | 5-CYCLO INDOLE COMPOUNDS AS 5-HT1D RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-06-04 | — | — | WO | disclosed |
| US-4945160-A | Preparation of certain 7-substituted quinolones | WARNER-LAMBERT COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | PDK4 2875/4885GRM5 159/4885GRM1 152/4885 |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | PDK4 646/4885GRM5 2449/4885GRM1 3380/4885 |
| US-10752622-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | PDK4 2453/4885GRM5 172/4885GRM1 164/4885 |
| US-10954229-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | PDK4 2453/4885GRM5 172/4885GRM1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.